Erin Scott, PA
Physician Assistant · Brandywine, MDNPI 1699320374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 24.4% of the total. Reporting peaked in 2021 at $305 and has fallen 95.5% since, to $14 in 2024.
Across 41 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$163
- Biohaven Pharmaceuticals, Inc.$122
- AstraZeneca$113
- Astellas Pharma US Inc$92
- Biohaven Pharmaceutical Holding Company Ltd.$62
- Pfizer$62
- plus $54 from 3 others
What the payments were for
- Food & beverage$667100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $163 |
| Biohaven Pharmaceuticals, Inc. | 7 | $122 |
| AstraZeneca | 8 | $113 |
| Astellas Pharma US Inc | 6 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| Pfizer | 4 | $62 |
| GSK | 2 | $29 |
| Novo Nordisk | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$667 in reported general payments places this provider in the 70th percentile of 2,567 physician assistant providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,139 |
| Rosuvastatin Calcium | 30 | $639 |
| Atorvastatin Calcium | 66 | $592 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $335 |
| Omeprazole | 18 | $225 |
| Losartan Potassium | 21 | $184 |
| Amlodipine Besylate | 25 | $125 |
| Levothyroxine Sodium | 16 | $120 |
| Allopurinol | 12 | $93 |
| Metformin Hcl | 15 | $57 |
| Carvedilol | 14 | $47 |
| Hydrochlorothiazide | 12 | $41 |
| Lisinopril | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other physician assistant in Brandywine
- Margaret JoyceTowson$220K
- Kara CossisBaltimore$177K
- Garland JamesSilver Spring$86K
- Melissa BearekmanBaltimore$81K
- Brittany YerkesSalisbury$81K
- Amy CollierTimonium$29K
- Hannah JohnsonNottingham$27K
- Lisa FoxAnnapolis$26K
- Praveena GadamBaltimore$24K
- Jinhui YuanFrederick$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.